stockportfolio.pro
Glaukos Corporation (GKOS)
Healthcare · Medical Devices · NYSE
Glaukos Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114.40M | $159.25M | $181.28M | $236.98M | $224.96M | $294.01M | $282.86M | $314.71M | $383.48M | $507.44M |
| Gross profit | $98.22M | $138.20M | $156.20M | $198.40M | $133.24M | $227.38M | $213.88M | $239.14M | $289.45M | $282.76M |
| Net income | $4.52M | $-92,000 | $-12.95M | $15.42M | $-120.35M | $-49.59M | $-99.19M | $-134.66M | $-146.37M | $-187.69M |
| Net margin | 4.0% | -0.1% | -7.1% | 6.5% | -53.5% | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% |
Source: Glaukos Corporation SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Glaukos Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GKOS in your portfolio →
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corporation — frequently asked questions
What is Glaukos Corporation's revenue?
Glaukos Corporation (GKOS) reported revenue of $507.44M for fiscal year 2025, up 32.3% from the prior year, according to its SEC filings.
Is Glaukos Corporation profitable?
No — GKOS reported a net loss of $-187.69M in fiscal 2025.
What is GKOS's P/E ratio?
Glaukos Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Glaukos Corporation growing?
GKOS's revenue grew at roughly 17.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Glaukos Corporation's official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.